Thus, the successful use of DNMT and HDAC (Histone deacetylases) inhibitors for chemotherapy re-sensitization in ovarian cancer cell lines and animal models imply that epigenetic therapies could be a future method for clinical chemo re-sensitization [40]. This evidence concerns the gene DNMT1 and ovarian carcinoma.